Yahoo Search Búsqueda en la Web

  1. Cerca de 9.090.000 resultados de búsqueda

  1. Rushmore (Brasil: Três é Demais) é uma comédia estadunidense de 1998 dirigida por Wes Anderson. O adolescente Max se apaixona pela nova professora da primeira série na escola. Para conquistá-la, ele pede conselhos ao pai de seus amigos, um milionário excêntrico. Porém, a situação se complica quando o novo amigo de Max também se envolve com a professora, iniciando uma verdadeira ...

  2. 22 de abr. de 2020 · Members. 山本 光夫. Mitsuo YAMAMOTO. 教授・博士(工学) Professor, Ph.D. (Engineering) 国際農業開発学コース (IPADS) 担当 In charge of IPADS program. 専門:環境科学(水圏環境化学・環境化学工学). Environmental Science (Aquatic Environmental Chemistry, Environmental Chemical Engineering) 羽根 由 ...

  3. en.wikipedia.org › wiki › TanakaTanaka - Wikipedia

    Hisao Tanaka, also known as Martin Tanaka (died 1991), American professional wrestler. Tanaka Hisashige (田中 久重, 1799–1891), Japanese rangaku scholar, engineer and inventor. Hisayoshi Tanaka (田中 久喜, born 1979), Japanese swimmer. Ichimatsu Tanaka (田中 一松, 1895–1983), Japanese academic, art historian and curator.

  4. filmap.tumblr.com › post › 131483181136Filmap

    19 de oct. de 2015 · Rushmore Wes Anderson. 1998. Max’s house 219 E 11th St, Houston, Texas 77008, United States See in map. See in imdb

  5. Aquí nos gustaría mostrarte una descripción, pero el sitio web que estás mirando no lo permite.

  6. Tres es multitud es una película de 1998, dirigida por Wes Anderson y protagonizada por Jason Schwartzman y Bill Murray. Voces adicionales Alondra Hidalgo Enzo Fortuny Eduardo Garza José Antonio Macías Víctor Ugarte Miguel Ángel Ghigliazza Patricia Quintero Sergio Gutiérrez Coto Benjamín Rivera

  7. Sara Sandifer is a member of the firm’s Healthcare Sector with a focus on Biotech and Pharma, and she leads the US Research Team across Biopharma, MedTech, and Health Tech practice areas. During her Russell Reynolds tenure, she has focused on biotech company building for clients ranging from VC-backed startups to Fortune 500 pharma and most recently is focused on biotech board evolution.